mAnaging siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE)
Did you know that Nigeria has 4.4 million people living with Sickle Cell Disease (SCD) and that more than 75% of annual sickle cell anemia births occur in Nigeria? If you have SCD, you know the impact it can have on your daily life. SCD can cause some intense pain, called “pain crises”, and other problems that can result in an emergency room or hospital visit.
The current use of Hydroxyurea in Sub-Saharan Africa is less than 1% among people living with SCD. Many people with SCD in Africa do not receive Hydroxyurea, though it is effective at decreasing negative health outcomes related to SCD. The good news is that Hydroxyurea can help adults and children with SCD have fewer pain crises and live longer.
-
Sickle Cell Disease (SCD) is a blood disease that caues problems with red blood cells. Learn more here.
-
Hydroxyurea is an international scientifically proven treatment for people living with SCD. Learn more here.
-
Learn about how we are training healthcare providers in the adoption of Hydroxyurea to improve SCD management. Read more here.
-
